Miltefosine
- CAS No.
- 58066-85-6
- Chemical Name:
- Miltefosine
- Synonyms
- HPC;C16:0;mil;HEPC;IMpavido;Miltefosin;HEXADECYLPHOSPHOCHOLINE;d18506;Miltex;C16 : O
- CBNumber:
- CB6370752
- Molecular Formula:
- C21H46NO4P
- Molecular Weight:
- 407.57
- MOL File:
- 58066-85-6.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/8/21 22:41:43
| Melting point | 232-234° (dec) |
|---|---|
| storage temp. | room temp |
| solubility | H2O: soluble10mg/mL, clear, colorless |
| form | Crystalline solid |
| color | White to Almost white |
| InChI | InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3 |
| InChIKey | PQLXHQMOHUQAKB-UHFFFAOYSA-N |
| SMILES | O(CCCCCCCCCCCCCCCC)P([O-])(=O)OCC[N+](C)(C)C |
| CAS DataBase Reference | 58066-85-6(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301 | |||||||||
| Precautionary statements | P264-P270-P301+P310-P405-P501 | |||||||||
| Hazard Codes | Xn | |||||||||
| Risk Statements | 22-43 | |||||||||
| Safety Statements | 36/37 | |||||||||
| RIDADR | UN 2811 6.1 / PGIII | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | KH2890000 | |||||||||
| HS Code | 29239000 | |||||||||
| Toxicity | LD50 in rats (mg/kg): 246 orally (Muschiol) | |||||||||
| NFPA 704 |
|
Miltefosine price More Price(4)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | M5571 | Miltefosine ≥98% (perchloric acid titration) | 58066-85-6 | 50MG | ₹10045.6 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | M5571 | Miltefosine ≥98% (perchloric acid titration) | 58066-85-6 | 100MG | ₹17449.9 | 2022-06-14 | Buy |
| TCI Chemicals (India) | M2445 | Miltefosine | 58066-85-6 | 100MG | ₹4300 | 2022-05-26 | Buy |
| TCI Chemicals (India) | M2445 | Miltefosine | 58066-85-6 | 1G | ₹14700 | 2022-05-26 | Buy |
Miltefosine Chemical Properties,Uses,Production
Description
Miltefosin, representing the prototype of a new phospholipid structure, was introduced for the palliative treatment of skin metastases in patients with breast cancer. It is highly active against the human leukemia tumor cells xenograft in nude mice, leading to growth inhibition and regression of large established tumors. Its mode of antitumor activity is not mediated by the host immune system but by its pharmacological effects at the level of the cancer cell membrane, distinctly different from that of the classical cytostatic drugs which interact with cell proliferation at the level of DNA replication. Protein kinase C inhibition has been suggested as a possible mechanism.
Uses
A phospholipid drug with antineoplastic and antiprotozoal/antifungal properties, also acts as an Akt inhibitor, and under investigation as a potential therapy against HIV infection.
Definition
ChEBI: A phospholipid that is the hexadecyl monoester of phosphocholine.
Antimicrobial activity
Concentrations of 1–5 μm inhibit the promastigotes and amastigotes of Leishmania spp. and the epimastigotes and amastigotes of T. cruzi. Inhibitory concentrations against T. brucei spp. and E. histolytica are closer to 50 μm. Acanthamoeba spp. are variably susceptible, depending on the experimental conditions.
Acquired resistance
There are no reports of clinical resistance in Leishmania so far. Experimental resistance has been induced in vitro against the promastigote stage of Leishmania and two plasma membrane proteins, LdMT and Ld Ros3, are necessary for miltefosine uptake. There is evidence that reduced sensitivity of promastigotes is passed on to intracellular amastigotes.
Pharmaceutical Applications
An alkylphospholipid, originally investigated as an anticancer compound, formulated for oral administration.
Pharmacokinetics
In rodent models the drug is almost completely absorbed after
oral administration. About 90% is bound to plasma proteins. It
is widely distributed in the body; studies in rats showed highest
uptake in kidney, liver and spleen. In rats and dogs bioavailability
was 82% and 94%, with maximum values reached after 4–48 h.
In adult human trials repeated oral dosing with 100 mg per
day achieved a peak plasma concentration of 70 mg/L after
8–24 h (day 23). The half-life is 6–8 days.
Clinical Use
Visceral leishmaniasis
Cutaneous leishmaniasis
Side effects
Mild to moderate gastrointestinal side effects are reported in 40–60% of patients. Moderate to severe nephrotoxicity was seen in 2% and 1% of patients, respectively; increases in creatinine levels were reversible. Miltefosine is contraindicated in pregnancy, based on findings of teratogenicity in rats. It causes hemolysis and cannot be given intravenously.
Miltefosine Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Zydus Lifesciences Ltd. | +91-0265-2315243 +91-6358895661 | Gujarat, India | 89 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| Clearsynth Labs | 91-22-45045900 | Maharashtra, India | 3889 | 58 | Inquiry |
| Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
| Beijing Mesochem Technology Co.,Ltd | +8613651027935 | China | 191 | 58 | Inquiry |
| Hebei Chuanghai Biotechnology Co,.LTD | +86-13131129325 | China | 5870 | 58 | Inquiry |
| Shaanxi Haibo Biotechnology Co., Ltd | +undefined18602966907 | China | 1000 | 58 | Inquiry |
58066-85-6(Miltefosine)Related Search:
1of4
chevron_right